Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.
Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, Rosinol L, Minnema M, Teipel R, van Doesum J, Hänel M, Lenain P, Botella-Garcia C, Koenecke C, Ducastelle S, Sanz J, Schroyens W, Zuckerman T, Monaco F, Koster L, de Wreede L, Hayden PJ, Schönland S, Yakoub-Agha I, Beksac M. Vincent L, et al. Among authors: teipel r. Bone Marrow Transplant. 2022 Mar;57(3):499-501. doi: 10.1038/s41409-021-01560-y. Epub 2022 Jan 10. Bone Marrow Transplant. 2022. PMID: 35013536 No abstract available.
Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
Kubasch AS, Peterlin P, Cluzeau T, Götze KS, Sockel K, Teipel R, Jentzsch M, Attalah H, Sebert M, Chermat F, Gloaguen S, Puttrich M, Cross M, Schneider M, Kayser S, Schipp D, Giagounidis A, Tirado-Gonzalez I, Descot A, van de Loosdrecht A, Weigert A, Metzeler KH, Fenaux P, Medyouf H, Platzbecker U, Ades L. Kubasch AS, et al. Among authors: teipel r. Leukemia. 2023 Nov;37(11):2309-2313. doi: 10.1038/s41375-023-02029-1. Epub 2023 Sep 21. Leukemia. 2023. PMID: 37735558 Free PMC article. Clinical Trial. No abstract available.
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.
Link CS, Teipel R, Heidenreich F, Rücker-Braun E, Schmiedgen M, Reinhardt J, Oelschlägel U, von Bonin M, Middeke JM, Muetherig A, Trautmann-Grill K, Platzbecker U, Bornhäuser M, Schetelig J. Link CS, et al. Among authors: teipel r. Bone Marrow Transplant. 2016 Jun;51(6):793-8. doi: 10.1038/bmt.2015.339. Epub 2016 Jan 11. Bone Marrow Transplant. 2016. PMID: 26752141
Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial.
Schetelig J, Link CS, Stuhler G, Wagner EM, Hänel M, Kobbe G, Böttcher S, Kreuzer KA, Middeke JM, Sockel K, Teipel R, von Bonin M, Stölzel F, Kramer M, Stilgenbauer S, Hallek M, Bornhäuser M; Deutsche CLL Studiengruppe and the German Cooperative Transplant Study Group. Schetelig J, et al. Among authors: teipel r. Br J Haematol. 2019 Mar;184(5):833-836. doi: 10.1111/bjh.15181. Epub 2018 Mar 12. Br J Haematol. 2019. PMID: 29528122 Free article. Clinical Trial. No abstract available.
Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Middeke JM, Kollinger F, Baldauf H, Stölzel F, Wermke M, von Bonin M, Sockel K, Link CS, Teipel R, Röllig C, Thiede C, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J. Middeke JM, et al. Among authors: teipel r. Biol Blood Marrow Transplant. 2018 Sep;24(9):1947-1951. doi: 10.1016/j.bbmt.2018.05.021. Epub 2018 May 21. Biol Blood Marrow Transplant. 2018. PMID: 29793046 Free article.
Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma.
Fasslrinner F, Stölzel F, Kramer M, Teipel R, Brogsitter C, Morgner A, Arndt C, Bachmann M, Hänel M, Röllig C, Kotzerke J, Schetelig J, Bornhäuser M. Fasslrinner F, et al. Among authors: teipel r. Biol Blood Marrow Transplant. 2020 Apr;26(4):691-697. doi: 10.1016/j.bbmt.2019.11.007. Epub 2019 Nov 12. Biol Blood Marrow Transplant. 2020. PMID: 31730919 Free article.
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial.
Hölig K, Schmidt H, Hütter G, Kramer M, Teipel R, Heidrich K, Zimmer K, Heidenreich F, Blechschmidt M, Torosian T, Ordemann R, Kroschinsky F, Rücker-Braun E, Gopsca L, Wagner-Drouet EM, Oelschlaegel U, Schmidt AH, Bornhäuser M, Ehninger G, Schetelig J. Hölig K, et al. Among authors: teipel r. Bone Marrow Transplant. 2021 Mar;56(3):635-645. doi: 10.1038/s41409-020-01053-4. Epub 2020 Oct 7. Bone Marrow Transplant. 2021. PMID: 33028987 Free PMC article. Clinical Trial.
Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation.
Sarraf AA, Schetelig J, Baldauf H, Stölzel F, Middeke JM, Sockel K, Teipel R, Brückner S, Berning M, Zeissig S, Babatz J, Baretton GB, Hampe J, Bornhäuser M, Aust D, Schmelz R. Sarraf AA, et al. Among authors: teipel r. Exp Hematol. 2022 Apr;108:36-45. doi: 10.1016/j.exphem.2022.01.005. Epub 2022 Jan 13. Exp Hematol. 2022. PMID: 35033627 Free article.
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse.
Sockel K, Stölzel F, Hönl F, Baldauf H, Röllig C, Wermke M, von Bonin M, Teipel R, Link-Rachner C, Brandt K, Kroschinsky F, Hänel M, Morgner A, Klesse C, Ehninger G, Platzbecker U, Bornhäuser M, Schetelig J, Middeke JM. Sockel K, et al. Among authors: teipel r. Cancer Manag Res. 2022 Feb 15;14:547-559. doi: 10.2147/CMAR.S339846. eCollection 2022. Cancer Manag Res. 2022. PMID: 35210852 Free PMC article.
Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease.
Krüger T, Wehner R, Herbig M, Kräter M, Kramer M, Middeke JM, Stölzel F, List C, Egger-Heidrich K, Teipel R, Oelschlägel U, Wermke M, Jambor H, Wobus M, Schetelig J, Jöhrens K, Tonn T, Subburayalu J, Schmitz M, Bornhauser M, von Bonin M. Krüger T, et al. Among authors: teipel r. Front Immunol. 2022 Oct 12;13:1005554. doi: 10.3389/fimmu.2022.1005554. eCollection 2022. Front Immunol. 2022. PMID: 36311725 Free PMC article.
27 results